This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 80.16%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 80.2% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Dynavax Technologies (DVAX) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Dynavax Technologies (DVAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Dynavax Technologies (DVAX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -58.33% and 21.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris' (VTRS) Q4 Earnings In-Line, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) reports in-line Q4 earnings but misses on sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Bausch Health's (BHC) Q4 Earnings & Sales Beat, Shares Up
by Zacks Equity Research
Bausch (BHC) reports an increase in earnings and sales in the fourth quarter as the company???s business revives in the second half.
Editas (EDIT) Q4 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports a wider loss in the fourth quarter of 2022. The strategic reprioritization, announced last month, is expected to extend the company's cash runway into 2025.
Gilead (GILD) Reports Positive Data From Urothelial Cancer Study
by Zacks Equity Research
Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.
Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.
Wall Street Analysts See a 109.61% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 109.6% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805
by Zacks Equity Research
Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.
Incyte (INCY) Reports Positive Long-Term Data From HS Study
by Zacks Equity Research
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
by Zacks Equity Research
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.
Do Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants
by Zacks Equity Research
Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).
Dynavax Technologies (DVAX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx
by Zacks Equity Research
Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.
Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) beat earnings and revenues in the fiscal third quarter, driven by growth in the United States and Russian markets.
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 103.22%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 103.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Editas (EDIT) Moves Ahead With its Portfolio Reprioritization
by Zacks Equity Research
Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.
Implied Volatility Surging for Dynavax Technologies (DVAX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion
by Zacks Equity Research
Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels.
Surging Earnings Estimates Signal Upside for Dynavax Technologies (DVAX) Stock
by Zacks Equity Research
Dynavax Technologies (DVAX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
bluebird (BLUE) Q3 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.
Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Viatris (VTRS) Q3 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.